| Bioactivity | Zotarolimus (ABT-578) is a derivative of rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis[1][2]. | ||||||||||||
| Name | Zotarolimus | ||||||||||||
| CAS | 221877-54-9 | ||||||||||||
| Formula | C52H79N5O12 | ||||||||||||
| Molar Mass | 966.21 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Sandra E Burke, et al. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev. 2006 Jun 3;58(3):437-46. [2]. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. |
Zotarolimus
CAS: 221877-54-9 F: C52H79N5O12 W: 966.21
Zotarolimus (ABT-578) is a derivative of rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immun
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.